Table 2.

Patient and Hospital Characteristics by MOUD Type Received During Hospitalization

	Buprenorphine	Methadone	Statistical Significance
Total	44.0% (578)	56.0% (735)
^a Age	57.0 median 53.3 mean Range: 24, 85	62.0 median 59.0 mean Range: 23, 87	^***
^b Gender	M: 95.0% (549) F: 5.0% (29)	M: 95.9% (705) F: 4.1% (30)	N.S.
^b Race
Black/Non-Hispanic or Latino	20.2% (117)	36.5% (268)	^***
White/Non-Hispanic or Latino	79.8% (461)	63.5% (467)	^***

^b Received MOUD Prior to Admission	68.5% (396)	31.4% (231)	^***
^b Received Opioids Prior to Admission	7.8% (45)	8.3% (61)	N.S.
^b Received Opioids During Admission	22.7% (137)	40.5% (322)	^***
^b OUD-Related Infection During Admission	4.8% (28)	11.3% (83)	^***
^b OUD-Related Diagnosis During Admission	34.8% (201)	28.0% (206)	^*
^b Co-Occurring Psychiatric Disorder	75.6% (437)	61.2% (450)	^***
^b Co-Occurring Substance Use Disorder	59.5% (344)	46.7% (343)	^***
^a Length of Stay (days)	5.0 Median 6.7 Mean Range: 2 – 47	5.0 Median 8.3 Mean Range: 2 – 50	^***
^b Received ICU Services During Admission	14.7% (85)	17.1% (126)	N.S.
^b Received Surgical Services During Admission	4.0% (23)	6.6% (47)	^*
^b Hospital Size			^*
Small: 1 to 49 beds	11.2% (65)	4.2% (31)	^***
Medium: 50 to 99 beds	27.3% (158)	29.0% (213)
Large: 100+ beds	61.4% (355)	66.8% (491)
^b Hospital Location
Midwest	27.0% (156)	27.1% (199)	^**
Northeast	23.9% (138)	26.0% (191)
South	33.2% (192)	26.7% (196)
West	15.9% (92)	20.3% (149)

Table Notes.

Kruskal-Wallis Rank Sum Test

Pearson chi-square test

statistical significance: p < 0.05*; p < 0.01**; p < 0.001***

N.S. = Non-significant; MOUD = medication for opioid use disorder; See Table 1 footnotes for additional details.